Novo Nordisk’s CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.
Latest Ratings for NVO
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 2022 | Liberum | Downgrades | Hold | Sell |
| Dec 2021 | JP Morgan | Downgrades | Overweight | Neutral |
| Jan 2021 | Deutsche Bank | Initiates Coverage On | Buy |
